期刊
ASIAN JOURNAL OF SURGERY
卷 44, 期 1, 页码 247-253出版社
ELSEVIER SINGAPORE PTE LTD
DOI: 10.1016/j.asjsur.2020.06.004
关键词
Metastasis; Overall survival; Prognosis; Prostate sarcoma
类别
The study assessed the prognostic factors for patients with prostate sarcomas and found that negative distant metastasis and radical tumor resection were significantly associated with better overall survival. Age, tumor size, symptom duration, and chemo/radiotherapy were not significantly related to survival. There were differences in treatment regimens between Chinese and US patients, with a higher rate of radical surgery in the US cohort leading to better survival outcomes.
Background/objectives: To assess the effects of clinical factors and treatments on the overall survival (OS) of patients with prostate sarcomas. Methods: We reported 41 cases diagnosed with prostate sarcomas from eight hospitals in China and retrospectively analyzed the prognostic factors by combining our data with cases from five previously published cohorts, including one extra Chinese cohort and four cohorts from US cohorts. Additionally, we investigated the differences in treatment regimens between China (n = 66) and the USA (n = 74). Results: The median survival time of the 41 cases was 18.6 months (95% confidence interval [CI]: 13.9-23.2). The status of negative distant metastasis (P = 0.004) and radical tumor resection with negative margin (P = 0.001) were significantly associated with better overall survival, whereas age, tumor size, duration of initial symptoms, and chemo/radiotherapy were not significantly related to OS. The survival time was longer in patients with rhabdomyosarcoma than in those with leiomyosarcoma (P = 0.049). Combined analysis of the current and 5 prior cohorts showed that more patients in the US cohorts underwent radical surgery (P = 0.005), and the overall survival was better among those with radical cystoprostatectomy compared to those with radical prostatectomy alone (P = 0.008). Conclusion: Radical resection to achieve a negative margin contributes to better survival for patients with prostate sarcoma. (C) 2020 Asian Surgical Association and Taiwan Robotic Surgery Association. Publishing services by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据